These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Prospects and reflections on the research and development of next-generation malaria vaccines]. Xiao B; Huang ZH; Jiang LB Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):555-556. PubMed ID: 35128882 [TBL] [Abstract][Full Text] [Related]
9. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532 [TBL] [Abstract][Full Text] [Related]
11. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234 [TBL] [Abstract][Full Text] [Related]
12. The Advanced Development Pathway of the RTS,S/AS01 Vaccine. von Seidlein L Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502 [TBL] [Abstract][Full Text] [Related]
13. [Field evaluation and future applications of the world's first malaria vaccine]. Gao Q Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):551-552. PubMed ID: 35128880 [TBL] [Abstract][Full Text] [Related]
14. "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana. Darkwa S; de Wildt G; Dalaba M; Vidzro E; Ansah EK PLoS One; 2022; 17(6):e0268009. PubMed ID: 35675273 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. RTS,S Clinical Trials Partnership PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396 [TBL] [Abstract][Full Text] [Related]
17. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566 [TBL] [Abstract][Full Text] [Related]
18. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination]. Vandoolaeghe P; Schuerman L Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388 [TBL] [Abstract][Full Text] [Related]
19. Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status. Gyaase S; Asante KP; Adeniji E; Boahen O; Cairns M; Owusu-Agyei S BMC Public Health; 2021 Jan; 21(1):240. PubMed ID: 33509156 [TBL] [Abstract][Full Text] [Related]
20. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Agnandji ST; Fernandes JF; Bache EB; Ramharter M Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]